{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"submitter":["Nielsen TO"],"pagination":["5367-5374"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-ECPF-SMDB-2863"],"project":["EurocanPlatform"],"abstract":["Expression profiling studies have classified breast carcinomas into luminal, normal breast-like, HER2 expressing and basal-like groups, with the latter two associated with poor outcomes. This study's objectives were to define an immunohistochemical profile that identifies basal-like tumors, to identify the presence of potential drug targets, and to determine the prognostic significance of the basal-like immunophenotype in a large series with long-term follow-up. On a panel of 21 breast tumors with basal-like expression profiles, we determined that this subtype was immunohistochemically negative for estrogen receptor and HER2, but positive for basal cytokeratins, HER1 and/or c-KIT. Using breast carcinoma tissue microarrays representing 930 patients with 17.4 years mean follow-up, basal cytokeratin expression was associated with decreased disease-specific survival. HER1 expression was observed in 54% of cases positive for basal cytokeratins (vs. 11% of negative cases) and was associated with poor survival independent of nodal status and size. c-KIT expression was more common in basal-like tumors than in other breast cancers, but did not influence prognosis. A panel of four antibodies (ER, HER1, HER2, and cytokeratin 5/6) can accurately identify basal-like tumors and suggests candidate drugs for therapies targeting HER1 or c-KIT."],"repository":["biostudies-other"],"experiment_type":["transcription profiling by array"],"data_source":["EurocanPlatform"],"omics_type":["Unknown"],"volume":["10"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"species":["Homo sapiens"],"pubmed_authors":["Livasy C","Hu Z","Ragaz J","Karaca G","Gilks CB","Nielsen TO","Perou CM","van de Rijn M","Gown AM","Hernandez-Boussard T","Jensen K","Hsu FD","Dressler L","Cowan D","Cheang M","Akslen LA"],"additional_accession":[]},"is_claimable":false,"name":"Transcription profiling of human breast carcinoma tissues representing 930 patients with 17.4 years mean follow-up, basal cytokeratin expression was associated with decreased disease-specific survival","description":"Expression profiling studies have classified breast carcinomas into luminal, normal breast-like, HER2 expressing and basal-like groups, with the latter two associated with poor outcomes. This study's objectives were to define an immunohistochemical profile that identifies basal-like tumors, to identify the presence of potential drug targets, and to determine the prognostic significance of the basal-like immunophenotype in a large series with long-term follow-up. On a panel of 21 breast tumors with basal-like expression profiles, we determined that this subtype was immunohistochemically negative for estrogen receptor and HER2, but positive for basal cytokeratins, HER1 and/or c-KIT. Using breast carcinoma tissue microarrays representing 930 patients with 17.4 years mean follow-up, basal cytokeratin expression was associated with decreased disease-specific survival. HER1 expression was observed in 54% of cases positive for basal cytokeratins (vs. 11% of negative cases) and was associated with poor survival independent of nodal status and size. c-KIT expression was more common in basal-like tumors than in other breast cancers, but did not influence prognosis. A panel of four antibodies (ER, HER1, HER2, and cytokeratin 5/6) can accurately identify basal-like tumors and suggests candidate drugs for therapies targeting HER1 or c-KIT.","dates":{"release":"2016-04-14T14:52:24Z","publication":"2004 Aug","modification":"2016-04-14T14:52:24Z","creation":"2016-04-14T14:52:24Z"},"accession":"S-ECPF-SMDB-2863","cross_references":{"ArrayExpress":["E-SMDB-2863"],"EFO":["EFO_0000635","EFO_0000305"],"ArrayExpress files":["E-SMDB-2863"]}}